Investments

Buyout
  • Logo Neopharmed Gentili/ Medioanum Farma
    Buyout

    Neopharmed Gentili

    Italy

    Healthcare & life science
    Healthcare & life science

    Neopharmed Gentili represents the spin-off of the primary care business of Mediolanum Farmaceutici Group and is a leading pharmaceutical company in the Italian market focused on branded prescription drugs in cardiovascular, neurology and allergo-respiratory therapeutic areas, with a portfolio of off-patent and mostly proprietary products. Its flexible and asset-light business model makes Neopharmed Gentili an attractive commercial platform with a proprietary, reliable, and specialized sales force of over 400 pharma representatives.

    Deal team

We appreciate Ardian’s unique support on our growth path that helped us very much to become market leader and position us ideally for future growth.”

Daniel Schustermann Managing Director of Schustermann & Borenstein

It is an efficient team, determined and confident in its choices, and always attentive to its partners. The relationships of trust that the Ardian team builds over time, with the management teams and, beyond that, with the advisors around them, are part of their DNA.

David Aknin Lawyer